Pegfilgrastim biosimilar - Sandoz

Drug Profile

Pegfilgrastim biosimilar - Sandoz

Alternative Names: LA-EP2006; Zioxtenzo

Latest Information Update: 01 Mar 2017

Price : $50

At a glance

  • Originator Sandoz
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Febrile neutropenia

Most Recent Events

  • 27 Jan 2017 Regulatory submission withdrawn for Febrile neutropenia (Prevention) in European Union (SC)
  • 06 Dec 2016 Pooled efficacy and adverse event data from phase trials PROTECT1 and PROTECT2 in Febrile neutropenia presented at the 39th Annual San Antonio Breast Cancer Symposium (SABCS 2016)
  • 11 Feb 2016 Preregistration for Febrile neutropenia (Prevention) in European Union (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top